tradingkey.logo

COSCIENS Biopharma Inc

CSCI
View Detailed Chart

2.720USD

0.000
Close 09/19, 16:00ETQuotes delayed by 15 min
8.64MMarket Cap
LossP/E TTM

COSCIENS Biopharma Inc

2.720

0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

0.00%

1 Month

+3.42%

6 Months

-37.47%

Year to Date

-1.81%

1 Year

-34.38%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
276 / 689
Overall Ranking
423 / 4737
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.98% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.59M.
Fairly Valued
The company’s latest is -0.42, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 331.27K shares, decreasing 2.04% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.11.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Ticker SymbolCSCI
CompanyCOSCIENS Biopharma Inc
CEOMs. Anna Biehn
Websitehttps://www.cosciensbio.com/
KeyAI